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Mutations in the GIGYF2 (TNRC15) Gene
at the PARK11 Locus in Familial Parkinson Disease
Corinne Lautier,1,2,3 Stefano Goldwurm,4 Alexandra Du¨rr,2,3 Barbara Giovannone,1 William G. Tsiaras,1
Gianni Pezzoli,4 Alexis Brice,2,3 and Robert J. Smith1,*
The genetic basis for association of the PARK11 region of chromosome 2 with familial Parkinson disease (PD) is unknown. This study
examined the GIGYF2 (Grb10-Interacting GYF Protein-2) (TNRC15) gene, which contains the PARK11 microsatellite marker with the
highest linkage score (D2S206, LOD 5.14). The 27 coding exons of the GIGYF2 gene were sequenced in 123 Italian and 126 French
patients with familial PD, plus 131 Italian and 96 French controls. A total of seven different GIGYF2 missense mutations resulting in
single amino acid substitutions were present in 12 unrelated PD index patients (4.8%) and not in controls. Three amino acid insertions
or deletions were found in four other index patients and absent in controls. Speciﬁc exon sequencing showed that these ten sequence
changes were absent from a further 91 controls. In four families with amino acid substitutions in which at least one other PD case was
available, the GIGYF2 mutations (Asn56Ser, Thr112Ala, and Asp606Glu) segregated with PD. There were, however, two unaffected
carriers in one family, suggesting age-dependent or incomplete penetrance. One index case (PD onset age 33) inherited a GIGYF2
mutation (Ile278Val) from her affected father (PD onset age 66) and a previously described PD-linked mutation in the LRRK2 gene
(Ile1371Val) from her affectedmother (PD onset age 61). The earlier onset and severe clinical course in the index patient suggest additive
effects of the GIGYF2 and LRRK2 mutations. These data strongly support GIGYF2 as a PARK11 gene with a causal role in familial PD.Introduction
Parkinson disease (PD [MIM 168600]) is a neurodegenera-
tive disorder affecting 1%–2% of the population above
age 60.1 The cause of dopaminergic neuronal loss in the ni-
gro-striatal pathway and consequent bradykinesia, resting
tremor, muscular rigidity, and postural instability that
characterize PD is largely unknown. Although only 10%–
30% of PD is familial,2 there is strong interest in identify-
ing genes that contribute to familial PD, because these
genes are expected to deﬁne mechanisms and new thera-
peutic approaches that apply to more common, sporadic
forms of the disease.
Family-based whole-genome linkage scans have identi-
ﬁed 13 chromosomal loci (PARK1 to PARK13) that show
linkage to PD.3–14 Candidate-gene analysis at these geno-
mic loci linked to PD has identiﬁed eight causative genes
in PD (SNCA [MIM 163890], PARK2 [Parkin] [MIM
602544], UCHL1 [MIM 191342], PINK1 [MIM 608309],
PARK7 [DJ1] [MIM 602533], LRRK2 [MIM 609007],
ATP13A2 [MIM610513], andHTRA2 [MIM606441]).12,15–26
The mechanisms through which these genes contribute
to the development of PD have not yet been clearly
established. Autosomal-dominant transmission is associ-
ated with mutations in the SNCA, LRRK2, and, probably,
UCHL1 and HTRA2 genes, whereas the four other genes
are autosomal recessive. These genes only account for
a small proportion of PD cases, except in speciﬁc clinical
subgroups or populations. This is the case for the
G2019S mutation in the LRRK2 gene found in up to822 The American Journal of Human Genetics 82, 822–833, April 2018% of Ashkenazi Jews and 39% of North African Arabs
with PD but in only 1 to 3% of their corresponding
controls.27,28
The PARK11 locus on chromosome 2q36-37 was initially
identiﬁed by whole-genome linkage analysis in a popula-
tion of PD patients with at least one ﬁrst-degree affected
relative.8,29,30 This linkage region was not conﬁrmed in an-
other PD population.31 However, an earlier association
analysis,32 which represents a more powerful method for
identifying risk-factor genes,33 also revealed signiﬁcant as-
sociation between markers in the PARK11 region and PD.
The PARK11 locus corresponds to an 18 cM interval be-
tween microsatellite markers D2S396 and D2S338, with
LOD scores of 2.9 and 2.4, respectively,8,29,30 that contains
73 potential candidate genes (Figure 1). The PARK11 mi-
crosatellite marker D2S206, which has the highest LOD
score of 5.14, is contained within intron 21 of a 27-exon
gene encoding 1299 amino acids, which has been alter-
nately designated GIGYF2 (Grb10-Interacting GYF Protein
2)34 or TNRC15 (Trinucleotide Repeat-Containing 15). We
previously identiﬁed GIGYF2 by yeast two-hybrid screen-
ing as one of two homologous proteins, GIGYF1 (or
PERQ1) and GIGYF2, interacting through their GYF
domain with the Grb10 adaptor protein.34 Grb10 and
the GIGYF proteins are of interest for their potential in-
volvement in insulin-like growth factor (IGF) and insulin
signaling.34–39 Because the IGFs and insulin have impor-
tant effects in the central nervous system40,41 and are
potentially associated with PD,42–45 we investigated the
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Figure 1. Genetic Map of the PARK11 Locus, Extending from Markers D2S396 to D2S338
Microsatellite markers enclosed within boxes have been significantly linked to Parkinson disease.29 Dots indicate markers localized within the
respective genes. Gene-mapping data are from the National Center for Biotechnology Information (NCBI) website.Methods and Materials
Study Population
Index cases with familial Parkinson disease (PD) (n¼ 123), deﬁned
by the presence of at least one ﬁrst-degree affected relative (parent,
child, or sibling), and healthy controls (n ¼ 131) were obtained
from an ItalianDNAbank assembled by the Parkinson Institute, Is-
tituti Clinici di Perfezionamento (Milan, Italy) (Table 1). DNA from
a second set of patientswith familial PD compatiblewithdominant
transmission (n¼ 126) and controls (n¼96)was obtained from the
French ParkinsonDiseaseGenetics StudyGroup (Paris, France) (Ta-
ble 1). The clinical diagnosis of PD in both populations was estab-
lished according to widely accepted criteria.46,47 This required the
presence of bradykinesia and at least one of the following: restingThetremor, rigidity, and postural instability; a positive response to do-
paminergic therapy; the absence of atypical features or other causes
of parkinsonism. Control DNAs were from unrelated individuals
from the samepopulations. All controlswere free of symptoms sug-
gestive of PD,R 45 years old, andwith a negative family history for
movement disorders at least in their ﬁrst-degree relatives. The
project was approved by the local ethical authorities, and written
informed consent was obtained from all subjects.
The study population was analyzed for the LRRK2 G2019S
mutation. Six of the 123 Italian patients with familial PD (4.8%)
carried the G2019S mutation, which was absent from the 131
Italian controls.48 In the French population, only two of the 126
familial-PD patients (1.6%) and one of the 96 controls (1.0%)
carried the G2019S mutation.27,49American Journal of Human Genetics 82, 822–833, April 2008 823
Table 1. Population Phenotype Descriptions
Italian Population French Population
PD n ¼ 123 Control n ¼ 131 PD n ¼ 126 Control n ¼ 96
Parkinson age of onset, Control age of study entry
(Mean5 SD)
535 12 69 5 9 485 12 645 9
Young onset,% 21 years 0 4
Early onset,% 45 years 28 50
Late onset, > 45 years 95 72
At least one first-degree relative affected (%) 100 100
Only father affected (%) 25.6 33.9
Only mother affected (%) 24.0 32.2
Both parents affected (%) 0.8 0.9
Only siblings affected (%) 44.6 1.7
Only progeny affected (%) 0 6.0
At least one parent and one sibling affected (%) 5.0 18.3
At least one parent and one progeny affected (%) 0 4.4
At least one parent, one sibling and one progeny
affected (%)
0 1.7
At least one sibling and one progeny affected (%) 0 0.9
Consanguinity (%) 8 ND 0 ND
Sex ratio (F/M) 54/69 75/56 63/63 61/35
Resting tremor (%) 80 0 78.3 0
Bradykinesia (%) 99 0 93.0 0
Rigidity (%) 78 0 88.9 0
Dementia (%) 5.9 0 11.7 0
Disease duration (mean year5 SD) 14.05 6.4 0 10.25 9.4 0
Positive L-Dopa response (% of patients) 98 0 94 0
L-Dopa treatment duration (mean year5 SD) 11.55 6.6 0 8.255 6.25 0
The L-dopa response was considered positive when at least a 30% improvement was observed on the basis of clinical assessment.GIGYF2 Gene Sequencing and Mutation Analysis
Genomic-primer design for all exons was performed with Vector
NTI-Suite 6.0 (InforMax, Invitrogen). Each exon and at least 50 bp
of ﬂanking intronic sequence was PCR ampliﬁed from genomic
DNA with the primer pairs listed in Table 2. PCR ampliﬁcation
was carried out with Taq DNA polymerase (FastStart Taq, 5U/ml,
Roche) and 25 pmol of forward and reverse primers. PCR was per-
formed in 50 ml volumes with conditions of 95C for 2 min fol-
lowed by 35 cycles of 95C for 30 s, annealing temperature for
30 s (58C for exons 1,3,4,6,8–10,13–15,17,18,21,23–27; 53C for
exons 2,22; 47C for exons 5,19; 59C for exon 7; 56C for exons
11,12,16; and 61C for exon 20), and 68C for 1 min, with a ﬁnal
68C hold for 5 min. Exons 9 and 10 plus the intervening intron
were small enough to be ampliﬁed in a single PCR reaction. The
PCR products were puriﬁed via Montage PCR96 Plate vacuum
ﬁltration (Millipore) and sequenced with either the forward or re-
verse primer designed for the PCR ampliﬁcation, except for several
with a sequencing primer indicated by ‘‘seq’’ after the primer name
in Table 2. Sequencing products were analyzed on an ABI 3730xl or
ABI 3700 sequencer with Sequence Analysis 3.3 software (Applied
Biosystems). All 27 coding exons of the GIGYF2 gene were
sequenced in the 249 familial-PD cases and 227 controls. All mis-
sensemutations, deletions, and insertions were subcloned for con-
ﬁrmation. Puriﬁed PCR-ampliﬁcation products were vector ligated
with the TOPO-TA cloning sequencing kit (Invitrogen). At least six
recombinant colonies were selected at random for each variation
and sequenced.
After the completion of these analyses, the eight exons found to
contain mutations (exons 2, 4, 8, 9, 11, 14, 25, and 26) were PCR
ampliﬁed and sequenced in 91 additional DNA samples obtained
from the French Parkinson Disease Genetics Study Group.824 The American Journal of Human Genetics 82, 822–833, April 20Statistical Analysis
Data are presented as mean 5 standard deviation. A database
including genetic and phenotypic data for each PD patient and
control was constructed in Statview 5.1 (SAS Institute, Cary,
NC), and all statistical analyses were performed with this program.
Allelic frequency (q) of GIGYF2 gene variation was expressed as
relative frequency in 2n chromosomes (with ‘‘n’’ as the number
of subjects). Statistical signiﬁcance was determined by Chi square
testing (p< 0.05). Hardy-Weinberg equilibriumwas considered for
a Hardy-Weinberg Chi square test < 3.84.
Results
GIGYF2 was screened for mutations as a candidate gene at
the PARK11 locus by complete sequencing of all 27 coding
exons in the index cases of families with PD from Cauca-
sian populations (n ¼ 249). This included 123 unrelated
Italian PD patients and 126 unrelated French PD patients
with at least one affected ﬁrst-degree relative. For compar-
ison, sequencing of the 27 coding exons of GIGYF2 was
also performed in 131 Italian and 96 French unrelated
controls. The general characteristics of PD index cases and
controls are shown in Table 1. Although most patients
developed PD after age 45 (n ¼ 167), there were also cases
with early (n ¼ 78) and juvenile onset (n ¼ 4). Most
patients had only one affected ﬁrst-degree relative.
We identiﬁed seven different heterozygous amino acid
changes in the GIGYF2 gene in 12 unrelated index cases
with PD (PmutX) (Table 3). None of these seven GIGYF208
Table 2. GIGYF2 Gene Primers Used for PCR and Sequencing Analysis
Primer Code Sequence PCR Sequencing Primer Size (bp) PCR Size (bp)
GG2-E1F GTCTGTTCCTACCTCTCTCACT PCR 22 485 (E1F-E1R)
GG2-E1F seq ACAGGTTTCTTCACATA SEQ 17
GG2-E1R GTTTTCAGCGAGGCACATAA PCR SEQ 20
GG2-E2F CTGATACTTTGAGATAG PCR SEQ 17 643 (E2F-E2R)
GG2-E2R GCTCCTCCTGTTGGCTCTTT PCR SEQ 20
GG2-E3F TGCTAAGGACACATACAGTTGC PCR SEQ 22 735(E3F-E3R)
GG2-E3R TGATTTTCTCCCCTCCCCAA PCR SEQ 20
GG2-E4F GTGTTATTTAGATGGTTGCT PCR SEQ 20 728 (E4F-E4R)
GG2-E4R AAGTTCTCTATCCTCCTCCT PCR SEQ 20
GG2-E5F ATTTCACTATTCAACTGT PCR 18 910 (E5F-E5R)
GG2-E5F seq TTTATGGTGGTGAATGTGTGC SEQ 21
GG2-E5R CAAAAACACCTCTAATGCTCA PCR 21
GG2-E5R seq GATGTTCAATACTTA SEQ 17
GG2-E6F TAGAAAAATGGGAAAGTGAGTGTC PCR SEQ 24 807(E6F-E6R)
GG2-E6R TGGCATTATTTTCTCCTCAG PCR 20
GG2-E6R seq CTGATACAAAAGCAAAGAT SEQ 19
GG2-E7F GGCGTTTGTGTGTGTGGATGAGG PCR SEQ 23 625 (E7F-E7R)
GG2-E7R CTTTCCCTTATTTCAGTCC PCR SEQ 19
GG2-E8F CTTTAGAGTATGTTGCCTGG PCR SEQ 20 662 (E8F-E8R)
GG2-E8R TCTTATCGGGTTCTTTGGC PCR SEQ 19
GG2-E9-10F TTAGAGGATGCTGAAGAAG PCR SEQ 19 678 (E9-10F - E9-10R)
GG2-E9-10R GCATAAGCAGAAGCCTAACT PCR SEQ 20
GG2-E11F GTAGTTAGCCTTCACAGA PCR SEQ 18 296 (E11F-E11R)
GG2-E11R TAAGAGGAGACAAAAAGAAT PCR SEQ 20
GG2-E12F ATACCATTTAGAGTTGACCA PCR 20 873 (E12F-E12R)
GG2-E12F seq TGGCATTGTTGGGAGAAGTTAC SEQ 22
GG2-E12R GGGATGCTCAACTGGTATGT PCR SEQ 20
GG2-E13F TTGACAGATGCCACCTCG PCR SEQ 18 321 (E13F-E13R)
GG2-E13R GTGTTTCCGTGACTAATA PCR SEQ 18
GG2-E14F GATGTCTGAGTTTTTATTC PCR SEQ 19 325 (E14F-E14R)
GG2-E14R AGGTGAGACTTGAGAGCAGA PCR SEQ 20
GG2-E15F CTGAATAGACCACTTTGC PCR 18 557 (E15F-E15R)
GG2-E15F seq TTTCTAATAATGTCTCCTGGG SEQ 21
GG2-E15R CGCTTATCTCCACCTGAAAT PCR SEQ 20
GG2-E16F CAAATAACCTGGAGAACCTGC PCR 21 443 (E16F-E16R)
GG2-E16F seq GCAAATGACAAGAACAAG SEQ 18
GG2-E16R ATAAAAGAGATGCTGACT PCR SEQ 18
GG2-E17F GCTCATTTAGGCACAGGGA PCR SEQ 19 634 (E17F-E17R)
GG2-E17R CGGGCTTTTTGGCTGCTACG PCR 20
GG2-E17R seq AGCAATGTTTATGTCCTG SEQ 18
GG2-E18F GAGTGTTCCTGTGCTTGGTT PCR SEQ 20 239 (E18F-E18R)
GG2-E18R GGTCAGAGTTCCCAGATACA PCR SEQ 20
GG2-E19F ATACTTTTTACTCCAGAT PCR SEQ 18 538 (E19F-E19R)
GG2-E19R TGAGCAAAAACCAGAAAGAT PCR SEQ 20
GG2-E20F GCTTTCTCTGTCATCTCTAT PCR SEQ 20 516 (E20F-E20R)
GG2-E20R CTGGGTGATGGGAGTGAGAC PCR SEQ 20
GG2-E21F TGGAGTTGAGAGAAATGC PCR SEQ 18 308 (E21F-E21R)
GG2-E21R GTAACCACTAACCCATAAT PCR SEQ 19
GG2-E22F TATCTAAAAACAGGAATC PCR SEQ 18 329 (E22F-E22R)
GG2-E22R TAAAAAGATAAGAAGACAGT PCR SEQ 20
GG2-E23F CGCCAGCAGAGGGAGTTGAT PCR 20 550 (E23F-E23R)
GG2-E23F seq AGTATTATCTTTTCTGAC SEQ 18
GG2-E23R CATAGGTGTGGTCATTTTG PCR SEQ 19
GG2-E24F CATCCATCCAGTATTGCCA PCR SEQ 19 305 (E24F-E24R)
GG2-E24R GTCCTGCTCTGTCATTCCAC PCR SEQ 20
GG2-E25F ATGTGGTATGGATGTTGTGATTAT PCR 24 616 (E25F-E25R)
GG2-E25F seq TTACCAAGTGTCTGTCATTA SEQ 20
GG2-E25R TGGGAGATACACAAAGGT PCR 18
GG2-E25R seq CATTTCTTGGGTTACTCA SEQ 18
GG2-E26F CTGAGTGGGATGTCTTGGTCTA PCR 22 395 (E26F-E26R)
GG2-E26F seq AGGGTGAGCCAAGTCTGAATCTGC SEQ 24
GG2-E26R GCACTCCTCCAACACTCA PCR SEQ 18
GG2-E27F ACAGACTTACATTCCAGC PCR SEQ 18 246 (E27F-E27R)
GG2-E27R AAGAGTAAATGGTGAGTAAGTGT PCR SEQ 23The American Journal of Human Genetics 82, 822–833, April 2008 825
Table 3. GIGYF2 Mutations and Gene-Sequence Variation Identified in PD and Control Populations
Allele Frequency (q)
Exon
Variation
Reference
Nucleotide
Change
Amino Acid
Change
Distance
(bp)
Major
Alleles
PD
498 Chr.
Control
454 Chr. p Value
GIGYF2 Mutations
Ex2 PDmut-1 c.167A/G Asn56Ser (AAC-AGC) 16776 A 0.008 0.000 0.056
Ex4 PDmut-2 c.334A/G Thr112Ala (ACA-GCA) 25326 A 0.002 0.000 0.339
Ex8 PDmut-3 c.832A/G Ile278Val (ATA-GTA) 59866 A 0.002 0.000 0.339
Ex9 PDmut-4 c.1003T/A Ser335Thr (TCT-ACT) 60129 T 0.002 0.000 0.339
Ex11 PDmut-5 c.1370A/C Asn457Thr (AAT-ACT) 63886 A 0.006 0.000 0.098
Ex14 PDmut-6 c.1818C/G Asp606Glu (GAC-GAG) 78790 C 0.002 0.000 0.339
Ex25 PDmut-7 c.3625_3648del24 Del LPQQQQQQ 1209-1216 116588 0.004 0.000 0.184
Ex25 PDmut-8 c.3648_3649insCAACAG Ins QQ 1217 116611 0.002 0.000 0.357
Ex25 PDmut-9 c.3661_3672del12 Del PPQQ 1221-1224 116624 0.002 0.000 0.357
Ex26 PDmut-10 c.3724G/A Val1242Ile (GTA-ATA) 119378 G 0.002 0.000 0.339
Ex25 Ctrlmut-1 C.3512A/G His1171Arg (CAT-CGT) 116475 A 0.000 0.002 0.286
GIGYF2 Variants
Ex11 Variant-rs2289912 c.1378C/A Pro469Thr (CCT-ACT) 63894 C 0.018 0.020 0.843
Ex25 Variant-1 c.3613_3633del21 Del QQQQLPQ 1205-1211 116576 0.056 0.057 0.924
Ex25 Variant-rs10555297 c.3630_3632del3 Del Q 1210 116593 DelACA 0.464 0.457 0.843
Ex25 Variant-2 c.3633_3634insCAG Ins Q 1212 116596 0.016 0.021 0.555
Ex25 Variant-3 c.3673_3684del12 Del PQQQ 1225-1228 116636 0.018 0.007 0.144
GIGYF2 SNPs
Ex2 SNP-1 c.69T/C Ser23 (AGT-AGC) 16678 T 0.002 0.002 0.948
Ex8 SNP-2 c.828G/C Gly276 (GGG-GGC) 59862 G 0.002 0.002 0.948
Ex9 SNP-3 c.1047T/C Asp349 (GAT-GAC) 60173 T 0.002 0.000 0.407
Ex12 SNP-rs2305138 c.1554G/A Glu518 (GAG-GAA) 65187 G 0.054 0.035 0.159
Ex13 SNP-4 c.1716G/T Ala572 (GCG-GCT) 75626 G 0.006 0.000 0.150
Ex21 SNP-5 c.2835G/T Ser945 (TCG-TCT) 108989 G 0.004 0.000 0.241
Ex22 SNP-rs3816334 c.2940G/A Gln980 (CAG-CAA) 113169 G 0.281 0.319 0.198
Ex25 SNP-rs7563724 c.3630A/G Pro1210 (CCA-CCG) 116593 A 0.014 0.021 0.445
Ex25 SNP-rs12328151 c.3651G/A Pro1217 (CCG-CCA) 116614 G 0.227 0.225 0.948
Ex27 SNP-6 c.3855G/A Ser1285 (TCG-TCA) 125899 G 0.006 0.009 0.615mutations found in PD patients were observed in 227 con-
trols. They consist of seven single-nucleotide changes re-
sulting in amino acid substitutions in exon 2 (Asn56Ser),
exon 4 (Thr112Ala), exon 8 (Ile278Val), exon 9
(Ser335Thr), exon 11 (Asn457Thr), exon 14 (Asp606Glu),
and exon 26 (Val1242Ile) (Table 3, Figure 2). The Asn56Ser
substitution was found in four unrelated PD patients (one
Italian and three French), and the Asn457Thr substitution
was present in three unrelated PD patients (two Italian and
one French). All other amino acid substitutions were ob-
served only in a single PD patient. In contrast, sequencing
of all coding exons in 227 unrelated control individuals de-
tected a single 71-year-old healthy Italian woman without
a family history of PD, with an amino acid substitution in
exon 25 (His1171Arg, Ctrlmut-1) (Table 3, Figure 2), which
was not found in the PD population or other control sub-
jects. The eight exons shown to contain mutations in the
PD patients and the single control (exons 2, 4, 8, 9, 11,
14, 25, 26) then were sequenced in a further 91 control
DNA samples from the French Parkinson Disease Genetics
Study Group. In this set of additional controls, none of the
identiﬁed mutations and no new variations were found.
Most of the seven single amino acid substitutions identi-
ﬁed in GIGYF2 in patients represent conservative amino
acid sequence changes, but alignment of the human GI-
GYF2 protein sequence with 12 other species demonstrates826 The American Journal of Human Genetics 82, 822–833, April 2that they occur within highly conserved amino acid blocks
and involve residues that are highly, although not abso-
lutely, conserved across species (Figure 3). In addition,
these amino acid substitutions are signiﬁcantly more fre-
quent in PD patients (12 of 249) than in controls (1 of
227) (p < 0.003).
Among the 12 PD probands with GIGYF2 mutations,
eight had at least one parent affected, one had both par-
ents affected, and three had a single affected sibling (Fig-
ure 4). PD was present by medical history across three suc-
cessive generations in three of the families and across two
generations in ﬁve of the families (Figure 4). Among the
probands of families with GIGYF2 missense mutations,
there were a total of six females and six males with the di-
agnosis of PD, and the occurrence of PD in two or three
successive generations in most families is consistent with
autosomal-dominant inheritance. DNA samples were
available from at least one affected relative in four families.
In family 068-004, PD was present in three successive gen-
erations and the affected mother of the male proband was
shown to have the same Asp606Glu mutation (Figure 4).
The proband was diagnosed with PD at age 42, his mother
at age 83. In family 057-009, the male index case inherited
the Asn56Ser mutation from his affected mother. The age
of PD onset was 41 in the proband and 73 in the mother.
Among eight siblings of the proband, three were008
Figure 2. Chromatograms Illustrating GIGYF2 Gene Mutations
All show analysis by forward sequencing, except for the exon 4 (Thr112Ala) mutation, which was sequenced in reverse, and insertion
(Ins QQ 1217) and deletions (Del LPQQQQQQ 1209–1216 and Del PPQQ 1221–1224), for which individual alleles were sequenced after
subcloning.The American Journal of Human Genetics 82, 822–833, April 2008 827
Figure 3. Alignment of GIGYF2-Mutation Protein-Sequence Regions in Multiple Species
Overall identity of available amino acid sequences of various species with Homo sapiens (gi 42476299) is: Pan troglodytes (gi 114583902)
99%, Macaca mulatta (gi 109101490) 99%, Canis familaris (gi 73993973) 97%, Bos taurus (gi 156120403) 95%, Equus caballus (gi
149711637) 95%, Rattus norvegicus (gi 149016387) 94%, Mus musculus (gi 34365797) 93%, Gallus gallus (gi 118094814) 86%, Mono-
delphis domestica (gi 126314299) 86%, Danio rerio (gi 71834468) 56%, Xenopus laevis (gi 148223517) 56%, and Ornithorhynchus anatinus
(gi 149599305) 39%. The dotted lines correspond to sequence regions not yet available or sequence regions of known sequence but
nonhomology.genotyped. Two of these, a dizygotic female twin and
a brother, bear the same mutation but do not have clini-
cally apparent PD. Their ages at the time of most-recent
medical history were 61 and 73 years. Follow-up will be re-
quired to determine whether they ultimately develop PD.
Another unaffected brother, age 67, does not carry the
Asn56Ser mutation. In family 28-V-0056, the male index
case had an affected brother, and both carried the
Thr112Ala mutation. Although both brothers had onset
at age 43, neither their mother, who died at age 72, nor
their father, who died at age 52, had known PD (Figure 4).
In the Italian family 1034-D-0385, the female index case
inherited the Ile278Val candidate mutation from her fa-
ther. Sequence analysis of a second PD-associated gene,
LRRK2, in this family revealed the previously described
LRRK2 Ile1371Val mutation in the index case and her
mother.50 The father had PD onset at age 66, the mother
at age 61, and the index case bearing the two different
gene mutations had PD onset at the much earlier age of
31 years. She has had progressive, severe PD with marked
ﬂuctuations in clinical course in spite of initial response
to L-dopa therapy. At 50 years of age, she currently is par-
tially compensated on intraduodenal L-dopa infusions.
Three other nucleotide variations were found in four in-
dex cases with PD and none of the controls. They consisted
of a deletion of eight (Del LPQQQQQQ 1209–1216) and
four codons (Del PPQQ 1221–1224) and an insertion of
two codons (Ins QQ 1217) in exon 25 (Table 3). The Del
LPQQQQQQ 1209–1216 deletion was detected in two un-
related French PD patients. The InsQQ1217 insertion was
associated with the Asn457Thr missense mutation in a
patient with onset at age 43. These deletion and insertion
sequences are in a region of Gln (Q) and Pro (P) repeats in
exon 25 that is not conserved across species. Furthermore,
four other insertions and deletions have been observed in
this region,with similar frequencies inPDpatients and con-
trols. One was previously described in dbSNP (rs10555297,
Table 3), and three are new (Variant-1, -2, and -3, Table 3).
We therefore speculate that the rare deletion and insertion828 The American Journal of Human Genetics 82, 822–833, April 20sequences identiﬁed in PD patients could represent less-
frequent variants without functional signiﬁcance.
In addition, we found one amino acid substitution
already described in dbSNP (rs2289912) (Table 3), as well
as ten nonsynonymous SNPs, including four previously
described in dbSNP (SNP-rsxxxx) (Table 3), and six new
SNPs (SNP-X) (Table 3). All these variants appear to be poly-
morphisms on the basis of their similar frequencies in PD
cases and controls.
Discussion
Our study has examined GIGYF2 (TNRC15) as a candidate
gene for PARK11. This was accomplished by complete se-
quencing of all 27 coding exons of the GIGYF2 gene in
two different populations of Caucasian patients with fa-
milial PD and in population-matched controls (123 Italian
PD patients and 131 controls, and 126 French PD patients
and 96 controls). We found seven different missense muta-
tions in the GIGYF2 gene in 12 index patients with PD
from Italy (n ¼ 7) and France (n ¼ 5). The following evi-
dence supports the pathogenic role of these amino acid
changes: i) they are not found in geographically matched
controls (a single amino acid change was detected in
only one of 127 controls) (p < 0.003); ii) the seven PD
missense mutations (Asn56Ser, Thr112Ala, Ile278Val,
Ser335Thr, Asn457Thr, Asp606Glu, and Val1242Ile) and
the control mutation (His171Arg) were absent from an ad-
ditional 91 controls; iii) they involve amino acids that are
relatively conserved across 12 nonhuman species; iv) when
available affected relatives were sampled, they were also
found to carry the same missense mutation (except for
one of the parents in the case with bilineal transmission
of PD). These data provide strong support for a role of mu-
tations in the GIGYF2 gene as a frequent cause of familial
PD, at least in Italy and France, and as a major contributing
factor at the PARK11 locus. The other sequence variants
found in patients are probably not causative, because
they affect a nonconserved region containing highly08
polymorphic repeats rich in Q and P residues. They are
more likely rare polymorphisms.
The 12 index cases with PD and GIGYF2missense muta-
tions include six women and six men with a mean age at
onset of 48.75 10.2 years (range 33–68). The clinical fea-
tures of these patients did not differ from those of patients
with typical idiopathic PD (Table 4). Unilateral tremor and
bradykinesia appeared at onset in most of the mutation
carriers, all of whom responded to L-dopa and developed
dyskinesia and/or motor ﬂuctuations as the disease pro-
gressed.
The GIGYF2 missense mutations are all found in the
heterozygous state compatible with autosomal-dominant
transmission. This inheritance pattern is also supported
by the observation of parent-child transmission in 11 of
the 12 pedigrees. However, age-dependent penetrance or
reduced penetrance is likely. In family 20-V-0056, the par-
ents of the two affected siblings died without being diag-
nosed with PD, and in family 757-028, two siblings with
the mutation are still healthy even though they are older
than their affected brother. It will be important to precisely
evaluate the penetrance ofGIGYF2mutations and to deter-
mine their frequency in idiopathic PD.
It has been suggested that interactions between multiple
genetic factors could have a role in the development of
PD.52 In the ﬁrst report on the PARK11 locus, the LOD
score of 5.14 for the entire study population was noted
to decrease to 4.12 when 11 of 65 families with known
Parkin mutations were excluded.30 In the present study,
we provide further evidence for gene interaction involving
the PARK11 locus in an individual with co-occurrence of
Ile278Val GIGYF2 and Ile1371Val LRRK2 mutations, who
had a much earlier onset of PD than did either parent
with single gene mutations. Given that GIGYF2 and
LRRK2 mutations have each been found in approximately
5% and 6% of familial PD patients, respectively, it should
be possible to identify additional patients with both muta-
tions to further test their potential interaction. Although
the functional role of the LRRK2 protein is not known,
it contains a mixed-function kinase-like sequence, and
the most common LRRK2 mutations (G2019S and
Arg1441Cys) enhance the kinase activity.53 Since GIGYF2
was initially identiﬁed through its binding to the Grb10
adaptor protein34 and Grb10 is thought to function by
linking proteins to tyrosine kinases,36 it will be important
in future studies to determine whether GIGYF2 interacts
with the LRRK2 kinase.
The function of the GIGYF2 protein is presently un-
known. Consistent with the development of a neurode-
generative disease in humans with GIGYF2 mutations,
GIGYF2 mRNA is strongly expressed in multiple regions
of the central nervous system (Novartis Gene Expression
Atlas). Together with the homologous GIGYF1 protein,
GIGYF2 was cloned from amouse-cDNA-expression library
by yeast 2-hybrid screening with an N-terminal fragment
of the Grb10 adaptor protein.34 The Grb10 N-terminus
contains a proline-rich region, and both GIGYF proteinsThecontain a GYF motif, which had previously been shown
to bind proline-rich sequences.54 With the yeast 2-hybrid
method, the GYF domains of GIGYF1 and GIGYF2 were
conﬁrmed to interact with the Grb10 proline-rich region.34
The GYF domain is named for a Gly-Tyr-Phe triad and
forms a bulge-helix-bulge structure important for binding
to proline sequences.54 On the basis of its ﬂanking amino
acid residues, the GYF domain of GIGYF2 can be classiﬁed
as a member of the SMY2 subtype.55 There is evidence that
this class of GYF domains has a preferred pro-rich binding
motif that is present in several proteins with roles inmRNA
splicing. GYF-domain-containing proteins in general are
hypothesized to function in mRNA splicing and/or other
aspects of mRNA processing, such as nuclear export.
The interaction between the GIGYF proteins and the
Grb10 adaptor protein evident in the yeast 2-hybrid sys-
tem has been conﬁrmed in mammalian cells expressing
endogenous levels of Grb10 and a myc-tagged GYF-do-
main-containing fragment of the GIGYF1 protein.34 Fur-
ther studies demonstrated that this fragment of GIGYF1
was recruited to activated IGF-I receptors, presumably
via the Grb10 adaptor. Of interest, overexpression of the
GIGYF1 fragment resulted in augmented IGF-I receptor sig-
naling. Similar studies with full-length GIGYF1 or GIGYF2
have not been possible, because the full-length proteins
form toxic inclusion bodies in cells when overexpressed,
presumably as a consequence of protein self-aggregation.34
In future experiments at GIGYF2 cellular concentrations
below the threshold for inclusion-body formation, it will
be important to determine whether the association of
GIGYF2 with PD involves its interaction with Grb10 and
the IGF and/or insulin signaling pathways. It will also be
important to determine whether the mutations that we
have identiﬁed lead to the development of PD by altering
GIGYF2 interactions with Grb10 and the IGF and/or insu-
lin pathways or other functions of the GIGYF2 protein.
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Table 4. Phenotype of Patients with GIGYF2 Mutations
Patient Number
677-O-
0092
057-
009
329-
013
757-
028
28-V-
0056
1034-D-
0385
283-Z-
0103
102-C-
0274
489-C-
0532
397-
011
068-
004
848-Z-
0079
GIGYF2 Mutation Asn56Ser Thr112Asp Ile278Val Ser335Thr Asn457Thr Asp606Glu Val1242Ile
Sex (M/F) M M F M M F F F F M M F
Origin (ITA/FR) ITA FR FR FR ITA ITA ITA ITA ITA FR FR ITA
Age of Onset (yr) 64 41 48 49 43 33 59 50 44 43 42 68
Disease Duration
at Examination (yr)
7 9 10 15 14 19 15 25 8 25 15 17
Resting Tremor  ND þ  þ þ þ þ þ þ þ þ
Bradykinesia þ ND þ þ þ þ þ þ þ þ þ þ
Rigidity þ ND þ þ þ þ þ þ þ þ þ þ
Dementia  ND          
L-Dopa Response þ ND þ þ þ þ þ þ þ þ þ þ
L-Dopa Duration (yr) 7 ND 8 10 10 15 13 21 3 25 7 17
UPDRS (ON) 14 ND ND 9 19 24 22 26 13 35 9 18
UPDRS (OFF) ND ND ND ND ND ND ND ND ND ND 16 37
H & Y (ON) 2.5 ND ND 1.5 2.5 3 3 3 2 2.5 2.5 2.5
H & Y (OFF) ND ND ND ND ND 4 3 ND ND ND ND 3
‘‘ND’’ denotes ‘‘not determined.’’
‘‘‘‘ denotes ‘‘phenotype absent.’’
‘‘þ’’ denotes ‘‘phenotype present.’’
‘‘ITA’’ denotes ‘‘Italy.’’
‘‘FRA’’ denotes ‘‘France.’’
‘‘UPDRS’’ denotes ‘‘Unified Parkinson’s Disease Rating Scale.’’51
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